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Diversity in makeup: How inclusive are beauty brands in the
USA?
Jennifer David, DO, MBA, Founder of Skin & Scripts Virtual
Dermatology, Philadelphia, PA; Callyn Iwuala, BA, Cooper Medical
School of Rowan University
Methods: 13 top makeup brands were selected for analysis. The hexadecimal color
codes were recorded and used to represent all available shades specific to
foundations. Using photoshop, the lightness values were extracted from each color
and values were then plotted. The number of shades for each lightness range was
counted and compared.
Results: The top 2 brands with the widest ranges of shades were Anastasia of Beverly
Hills Luminous and Lancome Teint Indole. The top 2 brands with the greatest
number of darker shades offered were Urban Decay Stay Naked Weightless and
Anastasia Beverly Hills. When comparing BIPOC owned brands to white owned
brands, 23% were BIPOC owned brands.
Conclusion: In conditions such as acne, scars, vitiligo, melasma, and postinflammatory hyperpigmentation, makeup has proven to serve as a beneficial camouflage,
elevating one’s self esteem and quality of life. Individuals with darker skin tones may
not be able to successfully mask their condition, because those shades do not exist in
most beauty brands. As our results highlight, a high number of shades does not
always correlate to a brand’s range and the inclusivity of all hues especially darker
skin tones. On average, the inclusivity and range of shades were similar between
BIPOC and white owned brands.
Commercial Disclosure: None identified.
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Vitiligo is a chronic autoimmune disease characterized by the destruction of
melanocytes, resulting in pale or white patches of skin. The population-based
Vitiligo and Life Impact Among International Communities (VALIANT) study sought
to understand the impact and burden of vitiligo on quality of life (QoL) from the
patient and physician perspective from around the world. The VALIANT study
recruited adult participants (aged $18 years who self-reported a vitiligo diagnosis)
via an online panel. Participants were asked questions regarding their mental health,
psychosocial burden, and behavior in professional and social situations. Separately,
health care professionals (HCPs; physicians, nurse practitioners, or physician
assistants) who treat patients with vitiligo completed an online-based questionnaire.
In the United States, 608 patients and 250 HCPs (166 dermatologists and 84 primary
care providers) participated in the survey. Confidence in the ability to improve QoL
and long-term psychological outcomes of their patients with vitiligo was noted in
67% and 58% of HCPs, respectively. HCPs and patients were asked the same
questions regarding avoidance/impact behaviors; concordance was achieved on
items such as wearing certain clothing to cover vitiligo lesions and avoiding going to
beach/pool/social events. However, HCPs often underestimated the impact of
vitiligo compared with the patient’s perspective in other areas, such as making
career choices (33% vs 51%), managing other medical diseases (25% vs 49%), and
obtaining other preventive care (20% vs 49%). In summary, increased understanding
between HCPs and patients with vitiligo regarding a holistic understanding of the
psychological burden and mental health of patients is needed.
Commercial Disclosure: This study was funded by Incyte Corporation.
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Background: The presence of melanocytic nevi (MN) is due to the accumulation of
melanocytes in the epidermis, dermis or both. A clinical-histopathologic concordance was sought in a previous study, where MN and other dermatoses were
included, finding a global concordance of 64%. There is no previous literature of
clinical-histopathologic concordance of MN in our population.
Objective: To determine clinical-histopathologic concordance of MN, and to
evaluate sensitivity, specificity, positive predictive value (PPV) and negative predictive value (NPV) of clinical diagnosis of MN. Cross-sectional, observational and
retrospective study from a registry of patients who requested medical care in an
outpatient dermatology clinic. Patients who underwent biopsy during a 2-year
period were included. We determined frequency and percentages of histopathologic findings from patients with a clinical diagnosis (by dermatologists) of MN.
Sensitivity, specificity, PPV and NPV of clinical diagnosis was evaluated. Data were
analyzed using the IBM SPSS Statistics program. From 102 biopsies, 41 were
included; 68.3% of patients were women, mean age was 40.37 years, the most
frequent topography was the head (82.9%). Diagnosis of MN was confirmed in
73.2% of biopsies. Lesions clinically confused with MN were mainly seborrheic
keratoses (14.6%) and basal cell carcinomas (4.9%). Sensitivity of clinical diagnosis
was 83.3%, specificity 83.3%, PPV 73% and NPV 90%.
Conclusion: diagnosis of MN was confirmed by histopathology in 73.2%, a higher
percentage when compared with previous literature. The diagnosis most frequently
confused with MN was seborrheic keratosis. Our findings highlight the importance
of the clinical diagnosis made by the dermatologist, which reached a sensitivity and
specificity of 83.3% in this study.
Commercial Disclosure: None identified.
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Dupilumab improves patient-reported outcomes among adults
with moderate-to-severe atopic dermatitis (AD) in clinical practice: 30-36 month results from the RELIEVE-AD study
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Wang, ScD, Analysis Group, Inc, Boston, MA; Gaelle Bego-Le-Bagousse, Sanofi,
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Introduction: This analysis of RELIEVE-AD, a prospective, longitudinal survey in US
adults with moderate-to-severe AD, evaluates the long-term impact of dupilumab
therapy on patient-reported AD flares, skin symptoms, itch, and sleep.
Methods: Adults prescribed dupilumab and enrolled in the US dupilumab patient
support program were invited to complete an online survey pre- (baseline) and postdupilumab initiation at months 1, 2, 3, 6, 9, 12, and 30e36. Participants reported
flares (increased itching/redness, new/spreading lesions) and sleep problems due to
AD (4- and 1-week recall, respectively), skin symptoms (skin pain, burning,
sensitivity; 1-week recall; range 0-10 [0 ¼ no symptoms]), and change in itch from
baseline.
Results: Of 698 patients completing the baseline survey, 425 (61.0%) responded at
Month 30e36 (mean age, 46.8 years; 61% female; 72% White). No AD flares were
reported by 33.8% of patients (Month 1) and 45.9% (Month 30e36) (P\.001 vs 3.0%
at baseline). Symptom scores for skin pain, burning, and sensitivity significantly
improved from 5.9, 5.2, and 5.5, respectively, at baseline to 2.7, 2.2, and 2.3 at Month
1 and 1.5, 1.2, and 1.2 at Month 30e36 (all P\.001 vs baseline). Change in itch from
baseline prior to dupilumab initiation was reported to be ‘‘very much better’’ by
75.3% of patients at Month 30-36. AD-related sleep problems were significantly
decreased to 27.1% (Month 1) and 13.4% (Month 30e36) (both P \.001 vs 77.5% at
baseline).
Conclusions: Dupilumab treatment in real-world clinical practice provides rapid and
sustained benefits for all patient-reported AD-related symptoms evaluated in
RELIEVE-AD.
Commercial Disclosure: This study was funded by Regeneron Pharmaceuticals,
Inc. and Sanofi.
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